Product Description
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Generalized anxiety disorder
Phase 2: Alcoholism|Alcohol-Related Disorders|Depressive Disorder, Major|Irritable Bowel Syndrome
Phase 1: Hypertension|Weight Loss|Overweight|Taste Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 12-DA-N475 | P1 |
Terminated |
Taste Disorders|Hypertension|Weight Loss|Overweight |
2015-09-01 |
|
| 11-AA-0010 | P2 |
Completed |
Alcoholism|Alcohol-Related Disorders |
2014-07-01 |
|
| CN148-015 | P3 |
Completed |
Generalized anxiety disorder |
2008-03-01 |
|
| CN148-013 | P2 |
Completed |
Irritable Bowel Syndrome |
2007-10-01 |